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BACKGROUND AND OBJECTIVE . In glioblastoma (GBM) patients who benefit from bevacizumab, it is unknown how long this treatment should be continued and whether it may be safely stopped. The aim of the present study was to describe the outcome of 36 responding GBM patients in whom bevacizumab was discontinued in the absence of tumour progression.
MATERIAL AND METHODS: We retrospectively reviewed the characteristics of GBM patients who received bevacizumab (10mg/kg every 2 weeks) either as first-line treatment in association with temozolomide radiochemotherapy (n=13) or at recurrence (n=23) in association with temozolomide, CCNU or irinotecan. In all of the patients, bevacizumab was discontinued while they had achieved a partial (63%) or a complete response (37%) according to RANO criteria. Reasons for bevacizumab discontinuation were physician's decision in 80% of cases and toxicity in 20% of cases.
RESULTS: In patients treated with first-line bevacizumab (median number of infusions = 4, range 1 to 44), median time to progression and median survival after bevacizumab discontinuation, were 11.8 months and 29 months, respectively. In patients treated with bevacizumab at recurrence (median number of infusions = 10, range 2 to 36), median time to progression and median survival after bevacizumab discontinuation were 6.9 months and 16 months, respectively. In none of the patients rebound tumor recurrence upon bevacizumab discontinuation was observed. At the time of tumor progression, 22 patients were re-treated with bevacizumab with a 53% response rate and a median progression-free survival of 6 months.
CONCLUSION: In responding patients, bevacizumab may be discontinued without rebound recurrence and a prolonged response may be observed in the absence of prolonged treatment. At the time of tumor progression, previously responding patients may benefit from bevacizumab re-challenge. INTRODUCTION: The current standard treatment for glioblastoma multiforme (GBM) has led a median, overall survival (OS) of 14.6 months, a 2-year progression-free survival (PFS) of 11% and a 2-year OS of 27.2%. The predominantly local failure pattern indicates the need to intensify local treatment. Radiation therapy dose escalation did not result in an improvement of tumor local control and patient survival. Hypofractionation could be an attractive alternative approach of dose intensification compared to dose escalation with conventional fractionation. It uses a higher dose per fraction to increase the biological effective dose, while shortening the overall treatment time. The aim of this phase II study is to evaluate safety and feasibility of hypofractionated RT in addition to chemotherapy, concomitant and adjuvant, following surgical resection, in patients with newly diagnosed GBM.
P08.44 PHASE II STUDY OF HYPOFRACTIONATED RADIATION
METHODS AND MATERIALS: From September 2013 to February 2016, 120 patients with newly diagnosed GBM were enrolled. This is a preliminary evaluation of the first 49 patients treated. Inclusion criteria were patients aged 18-70 years with KPS ≥60, patients aged >70 years with KPS ≥80, histopathologically confirmed of GBM or WHO grade III glioma IDH1 wild type and no codeletion 1p19q, estimated survival ≥ 3 months, tumor or surgical cavity ≤ 10 cm in its greatest diameter (including FLAIR area). All patients underwent surgical resection followed by hypofractionated radiation therapy, concomitant and adjuvant chemotherapy with temozolomide. The total dose prescribed was 60 Gy/ 4 Gy fraction/15 fractions (BED 10 84 Gy) on surgical cavity and eventual postoperative residual tumor on contrast-enhancing MRI and Methionine PET and 42 Gy/2.8 Gy fraction/15 fractions (BED 10 53.76 Gy) on the preoperative abnormality on FLAIR MRI. Clinical outcome was evaluated by neurological examination and MRI 1 months after RT and then every 3 months. Response was evaluated using the Response Assessment in Neuro-Oncology (RANO) criteria.
RESULTS: All 49 patients evaluated have carried out the treatment as planned and no interruption or severe toxicity occured. At the last observation time 15 (30.6%) patients are alive and 34 (69.4%) dead. The median, 1-and 2-year PFS were 14.9 months, 63% and 13.7%; the median, 1 and 2 years Disease-specific survival (DSS) were 16.2 months, 76.5% and 22.9%. Patients with age < 60 years, KPS 90-100, complete surgical resection, MGMT methylated status had better outcome with a median, 1 and 2 years DSS of 22.5 months, 85.7%, 33%; 22.4 months, 92%, 30%; 20.3 months, 86.9%, 35%; 20.3 months, 76.2%, 38.4% respectively.
CONCLUSIONS: Hypofractionated radiation therapy is a safe and feasible treatment for patients with newly diagnosed glioblastoma. INTRODUCTION: Recurrent Glioblastoma Multiforme (GBM) has limited treatment options and the prognosis is poor. Our group recently performed a high-throughput screen for novel DNA repair inhibitors which identified mibefradil dihydrochloride, a T-type calcium channel blocker. We and others subsequently revealed that mibefradil is active as a glioma radiosensitizer. More recent studies in our laboratory indicate that mibefradil blocks non-homologous end joining (NHEJ). Based on these findings, we sought to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of mibefradil and radiation therapy (RT), in a Phase I recurrent GBM study.
P08.45 MIBEFRADIL DIHYDROCHORIDE WITH
MATERIALS AND METHODS: The Primary objective was to determine mibefradil MTD when administered with concurrent hypofractionated RT. Secondary objectives included safety, pharmacokinetics (PK), progressionfree survival (PFS) and overall survival (OS). A tertiary objective included assessing intra-tumoral drug concentrations in patients enrolled in the translational sub-study within this trial. In this highly novel part of the study, patients were given mibefradil for 5 days prior to surgery, which was immediately followed by a re-resection. Resected tissues were then analyzed for the presence of drug in situ using LC/MS, in both T1-post contrast and FLAIR enhancing areas of disease; as identified by intraoperative MRI. Inclusion criteria included histologically proven GBM progressive or recurrent following RT and temozolomide. Patients received mibefradil, which was dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day was reached using a standard 3 + 3 design. RT consisted of 5 fractions of 600 cGy each, delivered over two weeks for a total of 3,000 cGy using stereotactic, intensity-modulated RT.
RESULTS: To date, 12 patients have enrolled including two translational patients, and 11 have been successfully treated. There were three DLTs, and a final dose level of 200 mg/day was reached. One patient experienced a complete radiographic response on MRI. The median PFS was 5.25 months and the median OS was 12.75 months. Intriguingly, Mibefradil was detected at micromolar levels in GBM tumor tissue in two patients enrolled in the translational sub-study. Of note, we detected drug levels in biopsies specifically from T1-post contrast and FLAIR regions of disease. These levels in the tumor correlate with that required for tumor cell radiosensitization in vitro.
CONCLUSIONS: Our preliminary data suggest mibefradil can be safely co-administered with RT over a 17 day period at 200 mg/day. Promising local control signals apparent in a selection of patients, and we have demonstrated adequate levels of the drug directly in resected brain tumor tissue. Based on the positive results of this study, we are now designing a Phase I trial testing the efficacy of this drug in front-line GBM.
P08.46 RECHALLENGE WITH BEVACIZUMAB IN A LONG-TERM SURVIVOR WITH GLIOBLASTOMA
S. Koeppen 1 , J. Hense 2 approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3-4 month prolongation of progression-free survival (PFS) without improving overall survival (OS). A 45-year-old female who underwent surgery for left fronto-temporal WHO grade II astrocytoma associated with epilepsy in 2005, 125I seed implantation at disease progression in 2009 and seed explantation 9 months later, was diagnosed with MGMT methylated GBM on the occasion of partial tumor resection in 2010 followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) chemotherapy, which was stopped after 4 months due to resection of a left temporal tumor cyst and recurrent cyst within 1 month. TMZ treatment causing prolonged thrombocytopenia was discontinued after 1 additional cycle. Immediately after this cycle, the patient experienced left median cerebral artery stroke resulting in right hemianopia, Broca's aphasia and severe hemiparesis of the right side. Three months later, BEV 10 mg/kg i.v. q14d was initiated, shortly interrupted for abdominal herniotomy in 2012, and continued for 3 years. Since 2014, concurrent low molecular weight heparin was given because of right lower limb deep venous thrombosis suspicion. Whereas GBM progression had not been detected for 2 years during anti-VEGF therapy, methionine PET MRI 6 months after BEV discontinuation revealed left temporal tumor recurrence. Rechallenge with BEV was initiated and the patient remained in stable clinical and radiographical condition for 10 months until now. This case highlights the utility of sequential BEV treatment in a patient being at high risk to develop chemotherapy-induced myelotoxicity. Long-term survival (> 3 years after diagnosis) in GBM has been attributed to patient-derived rather than tumor-derived factors. To our knowledge, this is the first description of effective long-term monotherapy with BEV for GBM and ongoing therapeutic response to single-agent BEV rechallenge in a patient with recurrent secondary GBM. Glioblastoma (GBM) is the most common brain cancer. Systemic therapy with temozolomide or nitrosoureas is often ineffective due to the activity of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT). Patients with recurrent GBM have limited treatment options and very poor prognosis. Dianhydrogalactitol (VAL-083) is a first-in-class bifunctional alkylating agent that rapidly induces interstrand DNA crosslinks targeting N7 of guanine leading to cell cycle arrest and apoptosis due to DNA double-strand breaks. VAL-083 readily crosses the blood-brain barrier, accumulates in brain tumor tissue and has shown activity in prior NCI-sponsored clinical trials against CNS tumors, including GBM and medulloblastoma. We have previously shown that VAL-083´s cytotoxic activity is independent of MGMT in contrast to temozolomide and nitrosoureas. We have also demonstrated VAL-083 is active against GBM cancer stem cells (CSCs) and acts as a radiosensitizer in GBM CSCs, in vitro. We have also previously shown that VAL-083 circumvents cisplatin-resistance and is less dependent on p53 activity than cisplatin suggesting a distinct mechanism of action for VAL-083. We recently completed enrollment of a Phase I/II clinical trial in the United States for recurrent GBM in patients who have failed temozolomide and bevacizumab (clinicaltrials.gov identifier: NCT01478178). Separate clinical trials are planned in GBM patients with high expression of MGMT both in recurrent bevacizumab-naive GBM patients (clinicaltrials.gov identifier: NCT02717962) and in newly diagnosed GBM patients utilizing MGMT promoter methylation as a validated biomarker for patient selection. Here we report new insights into VAL-083 mechanism of action by showing that VAL-083 rapidly induces interstrand DNA cross-links leading to irreversible S/G2 cell-cycle arrest and cell death caused by replication-dependent DNA damage. VAL-083 pulse-treatment leads to persistent phosphorylation of DNA double-strand break (DSB) sensors ATM, single-strand DNA-binding Replication Protein A (RPA32), and histone variant H2A.X. After 10 months in culture, following a standard protocol for inducing chemo-resistance, cancer cells remained sensitive to VAL-083 at low M concentrations. Taken together, these results support a unique molecular mechanism for VAL-083 that differs from both temozolomide, nitrosoureas or cisplatin. Our data further suggest that the mechanism of VAL-083 is impervious to important DNA-repair strategies employed by cancer cells to escape effects of alkylating agents commonly used in the treatment of GBM and that efficient resistance mechanisms against VAL-083 treatment are not easily acquired by cancer cells.
P08.47 DIANHYDROGALACTITOL (VAL-083) CAUSES BIFUNCTIONAL ALKYLATION LEADING TO IRREPARABLE DNA DOUBLE-STRAND BREAKS, S/G2 PHASE CELL-CYCLE ARREST AND TUMOR CELL DEATH IN AN MGMT INDEPENDENT MANNER OFFERING A UNIQUE TREATMENT PARADIGM FOR GBM
Tumors with histological features of pilocytic astrocytoma but with increased mitotic activity and additional high grade features (i.e. microvascular proliferation, necrosis) have been designated anaplastic pilocytic astrocytomas (APA). Patients with such tumors are thought to have an unfavorable clinical outcome. The status of APA as a separate entity has not yet been established and molecular features have only partially been elucidated. We analyzed a large retrospective series of 98 cases with histological features of APA by genome wide DNA methylation profiling, copy number analysis, targeted sequencing and, in a subset, panel sequencing. Unsupervised hierarchical clustering analysis of 450k methylation data together with over 250 reference cases of 13 established glioma classes (glioblastoma, astrocytoma, oligodendroglioma, pleomorphic xanthoastrocytoma, pilocytic astrocytoma, ganglioglioma, dysembryoplastic neuroepithelial tumor and diffuse leptomeningeal glioneuronal tumor) allowed the identification of a distinct methylation cluster comprising 73 APA ("APA core group"). Most of the remaining cases clustered into other tumor classes. The median age of the APA core group was 43 years with only 6/69 (9%) of cases occurring in pediatric patients; 56/67 (84%) were located in the cerebellum. The most frequent molecular alterations were deletions of CDKN2A/B (64/73, 87%) followed by alterations of the MAPK pathway (19/24, 79%, mostly NF1 mutations and BRAF fusions) and loss of ATRX (31/69, 45%). Outcome analysis confirmed an aggressive course with 12/28 (43%) patients deceased (median survival 13 months). In summary, APA is characterized by increased patient age, predominant cerebellar location, frequent MAPK pathway alterations, CDKN2A/B deletion, ATRX loss and unfavorable prognosis.
P08.49 THE VALUE OF NEUROCOGNITIVE TESTING IN MULTIMODAL RESPONSE ASSESSMENT IN PATIENTS WITH
GLIOBLASTOMA MULTIFORME A. Tinchon 1 , B. Calabek 1 , B. Andreas 2 , U. Riedlberger 1 , G. Minear 3 , B. Reinhard 3 , G. Liegl 4 , E. Freydl 5 , F. Marhold 6 , S. Oberndorfer 1 BACKGROUND: Due to several possible clinical and radiological pitfalls in response assessment, Tumorboard decision (TB) in patients with glioblastoma can sometimes be challenging. Early detection of recurrence in glioblastoma multiforme (GBM) is a crucial key factor for a prompt and effective second line therapy. Standard MRI sequences are the main diagnostic tool for follow up and the diagnosis of possible tumor recurrence. Additional MRI sequences, such as MRI-Diffusion and MRI-Perfusion imaging, or 18F-FET-PET (PET) imaging, may provide useful information in ambiguous cases of suspected recurrence. We performed a study addressing the question, whether additional neurocognitive assessment (NA) is in line with imaging results, as well as the TB.
METHODS: We consecutively enclosed twenty-five patients with histologically newly diagnosed GBM in a retrospective pilot study, counting for eighty-one (n=81) multimodal follow up (FU) test results. All patients were selected after receiving consecutive FU, comprising of MRI, PET and NA, using basically NeuroCogFX as neuropsychological test battery. Results were analysed for statistically significant correlations among themselves and over time. A consistency analysis was performed to demonstrate the impact
